Cidara Therapeutics Moving on FDA Advisory Committee Recommendation

(24/7 MARKET NEWS) – Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC reported, this morning, that the FDA Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that Cidara, as part of its New Drug Application (NDA), provided sufficient evidence supporting a favorable benefit-risk assessment for a limited use indication for rezafungin for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options.

Cidara Therapeutics opened this morning’s trading at $1.07 and is now at $0.9616, up $0.0335 (+3.61%), on volume of 10 million shares traded.

Its 52-week range is $0.40 to $1.60. Its next key inflection points are $1.41, $1.53, and this morning’s premarket high of $1.68. If can break through the $1.68 resistance level, on strong volume, it could try to challenge its February trading levels.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist